Age and diagnostic performance of Alzheimer disease CSF biomarkers
- 14 February 2012
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 78 (7), 468-476
- https://doi.org/10.1212/wnl.0b013e3182477eed
Abstract
Objectives: Core CSF changes in Alzheimer disease (AD) are decreased amyloid β1–42, increased total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal degeneration, and tangle pathology, respectively. These biomarkers identify AD already at the predementia stage, but their diagnostic performance might be affected by age-dependent increase of AD-type brain pathology in cognitively unaffected elderly. Methods: We investigated effects of age on the diagnostic performance of CSF biomarkers in a uniquely large multicenter study population, including a cross-sectional cohort of 529 patients with AD dementia (median age 71, range 43–89 years) and 304 controls (67, 44–91 years), and a longitudinal cohort of 750 subjects without dementia with mild cognitive impairment (69, 43–89 years) followed for at least 2 years, or until dementia diagnosis. Results: The specificities for subjects without AD and the areas under the receiver operating characteristics curves decreased with age. However, the positive predictive value for a combination of biomarkers remained stable, while the negative predictive value decreased only slightly in old subjects, as an effect of the high AD prevalence in older ages. Conclusion: Although the diagnostic accuracies for AD decreased with age, the predictive values for a combination of biomarkers remained essentially stable. The findings highlight biomarker variability across ages, but support the use of CSF biomarkers for AD even in older populations.This publication has 41 references indexed in Scilit:
- Diagnosis-Independent Alzheimer Disease Biomarker Signature in Cognitively Normal Elderly PeopleArchives of Neurology, 2010
- The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's diseaseNeurobiology of Aging, 2009
- Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjectsAnnals of Neurology, 2009
- Biomarkers in Relation to Cognitive Reserve in Patients with Mild Cognitive Impairment – Proof of ConceptDementia and Geriatric Cognitive Disorders, 2009
- Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss?Neuroscience Letters, 2009
- Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCINeurology, 2007
- Towards Complete and Accurate Reporting of Studies of Diagnostic Accuracy: The STARD InitiativeClinical Chemistry, 2003
- Congress CalendarHormone Research in Paediatrics, 2000
- Chromogranin A in Cerebrospinal Fluid: A Biochemical Marker for Synaptic Degeneration in Alzheimer’s Disease?Dementia and Geriatric Cognitive Disorders, 1995
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984